Effect of bifidobacterium breve on the intestinal microbiota of coeliac children on a gluten free diet: A pilot study by Quagliariello, Andrea et al.
nutrients
Article
Effect of Bifidobacterium breve on the Intestinal
Microbiota of Coeliac Children on a Gluten Free Diet:
A Pilot Study
Andrea Quagliariello 1,†, Irene Aloisio 2,†, Nicole Bozzi Cionci 2, Donata Luiselli 1,
Giuseppe D’Auria 3, Llúcia Martinez-Priego 3, David Pérez-Villarroya 3, Tomaž Langerholc 4,
Maša Primec 4, Dušanka Micˇetic´-Turk 5 and Diana Di Gioia 2,*
1 Laboratory of Molecular Anthropology, Centre for Genome Biology Department of Biological,
Geological and Environmental Sciences (BiGeA), University of Bologna, via Selmi 3, Bologna 40126, Italy;
andrea.quagliariello@unibo.it (A.Q.); donata.luiselli@unibo.it (D.L.)
2 Department of Agricultural Sciences, University of Bologna, viale Fanin 42, Bologna 40127, Italy;
irene.aloisio@unibo.it (I.A.); nicole.bozzicionci@studio.unibo.it (N.B.C.)
3 Sequencing and Bioinformatics Service, Fundación para el Fomento de la Investigación Sanitaria y
Biomédica de la Comunidad Valenciana (FISABIO-Salud Pública), Valencia 46020, Spain;
dauria_giu@gva.es (G.D.); martinez_lucpri@gva.es (L.M.-P.); enhancertrap@gmail.com (D.P.-V.)
4 Department of Microbiology, Biochemistry, Molecular Biology and Biotechnology,
Faculty of Agriculture and Life Sciences, University of Maribor, Pivola 10, Hocˇe 2311, Slovenia;
tomaz.langerholc@um.si (T.L.); masa.primec@um.si (M.P.)
5 Department of Pediatrics, Faculty of Medicine, University of Maribor, Taborska ulica 8, Maribor 2000,
Slovenia; dusanka.micetic@um.si
* Correspondence: diana.digioia@unibo.it; Tel.: +39-051-2096269
† These authors contributed equally to this work.
Received: 10 August 2016; Accepted: 13 October 2016; Published: 22 October 2016
Abstract: Coeliac disease (CD) is associated with alterations of the intestinal microbiota. Although
several Bifidobacterium strains showed anti-inflammatory activity and prevention of toxic gliadin
peptides generation in vitro, few data are available on their efficacy when administered to CD subjects.
This study evaluated the effect of administration for three months of a food supplement based on two
Bifidobacterium breve strains (B632 and BR03) to restore the gut microbial balance in coeliac children
on a gluten free diet (GFD). Microbial DNA was extracted from faeces of 40 coeliac children before
and after probiotic or placebo administration and 16 healthy children (Control group). Sequencing of
the amplified V3-V4 hypervariable region of 16S rRNA gene as well as qPCR of Bidobacterium spp.,
Lactobacillus spp., Bacteroides fragilis group Clostridium sensu stricto and enterobacteria were performed.
The comparison between CD subjects and Control group revealed an alteration in the intestinal
microbial composition of coeliacs mainly characterized by a reduction of the Firmicutes/Bacteroidetes
ratio, of Actinobacteria and Euryarchaeota. Regarding the effects of the probiotic, an increase of
Actinobacteria was found as well as a re-establishment of the physiological Firmicutes/Bacteroidetes
ratio. Therefore, a three-month administration of B. breve strains helps in restoring the healthy
percentage of main microbial components.
Keywords: coeliac disease; gluten free diet; probiotic; Bifidobacterium breve; intestinal microbiota;
qPCR; next generation sequencing
1. Introduction
Coeliac disease (CD) is a chronic gastrointestinal tract disorder showing damages at the small
intestine, which are hypothetically linked to an autoimmune response caused by gluten ingestion
in genetically predisposed subjects. CD in Europe and North America is estimated to affect about
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1% of the population, although its incidence in Western countries is increasing in the last decades [1,2].
CD is usually chronic but the lifelong adherence to a gluten-free diet (GFD) keeps the disease under
control: the small intestine returns to its physiological condition and subsequent tests for CD specific
autoantibodies are negative [3,4]. Even if the adherence to a GFD is the only effective solution against
CD, patients risk suffering from an unbalanced nutritional intake and difficulties to adhere to the strict
GFD are frequently reported.
The gut microbiota has a very close relation with the host contributing to the normal human
physiology. It can provide a barrier for colonization of pathogens, synthesize vitamins and other
beneficial compounds and stimulate the immune system. Environmental factors can lead to
a disturbance of the microbiota composition, disrupting microbiota-host mutualism and shifting from
a condition of homeostasis to a disease-associated profile [5]. In the last decade, CD has been associated
to an altered composition of the intestinal microbiota even though studies reported in literature show
that there is not a characteristic “coeliac intestinal microbiota” [6]. Some authors evidenced an intestinal
dysbiosis in CD patients with active disease characterized by a remarkable reduction in Gram positive
bacterial population in duodenal and faecal specimens facilitating the colonization of potentially
harmful Gram negative bacteria within the mucosal surface of CD patients [7–9]. In particular, data
obtained from duodenal biopsies revealed a reduction in the number of bifidobacteria [10] and changes
in species distribution within the Bifidobacterium genus have been evidenced by Denaturing Gradient
Gel Electrophoresis (DGGE) [11]. Moreover, symptom free CD patients adherent to a GFD at least
for two years did not completely restore the microbiota composition and this condition can lead to
a different metabolomics profile [9]. Bacteria belonging to the Bifidobacterium genus are well known
for their health promoting properties and for their capability of stimulating cells to produce immune
molecules and modulating the physiology of gut-associated lymphoid tissue (GALT) [12]. In particular,
in vitro studies have been focused on the capability of bifidobacteria to increase the IL-10 secretion
when co-incubated with mononuclear cells and faecal samples from CD patients [13]. Moreover,
a Bifidobacterium lactis strain and a probiotic product containing Lactobacillus and Bifidobacterium strains
resulted effective in reducing gliadin induced epithelial permeability through prevention of the toxic
gliadin peptide generation during in vitro digestion [14–16].
Despite the encouraging data on the potential of probiotic strains, particularly bifidobacteria,
in vivo studies in patients with CD remain still very scarce. Until now, only few studies have taken
into account the direct administration of bifidobacteria in subjects affected by CD. Smecuol et al. [17]
studied the effects of Bifidobacterium infantis natren life start strain in untreated CD patients or rather on
a gluten containing diet. Authors found that Bifidobacterium administration may alleviate symptoms
of untreated CD but it could not modify intestinal permeability. A second study [18] evaluated the
administration of Bifidobacterium longum CECT 7347 in children on a GFD with newly diagnosed
CD and it revealed a reduction of CD3+ T lymphocytes and TNF-α due to probiotic ingestion.
To date, no studies on CD considered the administration of Bifidobacterium breve strains although
this species has proven very successful in several paediatric trials regarding necrotizing enterocolitis,
immunodeficiency and constipation [19–21].
This work is aimed at the assessment of the impact of the administration of two Bifidobacterium breve
strains on the gut microbiota composition of coeliac patients compliant to a GFD and, at the same time,
it evaluates the difference in the intestinal colonization of coeliac subjects on a GFD for several years
with respect to healthy subjects.
2. Materials and Methods
2.1. Study Design and Samples Collection
The study was a double-blinded placebo controlled intervention including 40 patients affected
by CD and 16 healthy children for the Control group recruited at a single centre, Department of
Paediatrics, University Clinical Center Maribor in a period from October 2013 to June 2014. Children
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with CD, aged between 1 and 19 years, were positive to serologic markers for CD and positive for
small bowel biopsy, according to European Society for Paedriatric Gastroenterology Hepatology and
Nutrition (ESPGHAN) criteria for CD [22]. More details about patients (Table S1) and inclusion/exclusion
criteria of the recruiting process are available in Klemenak et al. [23]. The study was registered at
https://www.clinicaltrials.gov (registration number: NCT02244047). Patients affected by CD have been
randomly allocated into two groups: 20 in the Probiotic group and 20 in the Placebo group. The Probiotic
group of patients received an experimental formulation containing B. breve for three months and the
Placebo group received a placebo formulation for the same duration. Probiotic formulation was a mixture
of 2 strains, B. breve BR03 (DSM 16604) and B. breve B632 (DSM 24706) (1:1), administered as lyophilized
powder in a daily dosage of 109 Colony Forming Units (CFU) of each strain. Placebo was prepared with
the same excipients without probiotic strains using an identical form of package. Each package of 2 g
powder was mixed with fluids and ingested in the morning breakfast for three months.
Faecal samples of CD patients were collected twice, on enrolment (T0) and at the end of
intervention with probiotic/placebo (T1). Members of Control group were sampled only once.
Faecal samples were frozen immediately after collection at −80 ◦C, in numbered screw-capped plastic
containers, until they were processed for DNA extraction. Researchers carrying out DNA extraction
and molecular analyses (qPCR and sequencing) were blind to the group identity of patients (Control,
Probiotic or Placebo group).
2.2. DNA Extraction from Faecal Samples
DNA was extracted from 200 mg of faeces (preserved at −80 ◦C after collection) were used using
the QIAamp DNA Stool Mini Kit (Qiagen, West Sussex, UK) with a slight modification of the protocol:
An additional incubation at 95 ◦C for 10 min of the stool sample with the lysis buffer was added to
improve the bacterial cell rupture [24]. Extracted DNA was stored at −80 ◦C. The purity of extracted
DNA was determined by measuring the ratio of the absorbance at 260 and 280 nm (Infinite®200 PRO
NanoQuant, Tecan, Mannedorf, Switzerland) and the concentration was estimated by Qubit® 3.0
Fluorometer (Invitrogen, Life Technologies, Van Allen Way, Carlsbad, CA, USA).
2.3. Preparation of DNA Libraries for Illumina MiSeq Sequencing
The sample subjected to sequencing belonged to the following groups: 20 Probiotic group T0,
20 Probiotic group T1, 20 Placebo group T0, 20 Placebo group T1 and 16 Control group (Figure 1).
They were processed to amplify and sequence the V3-V4 region of the 16S rRNA gene.
The amplicons, approximately 460 bp in length, were generated using the forward and reverse primers,
respectively: 5′ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG 3′,
5′ GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC 3′, already
used in [25].
Each 25 µL PCR reaction contained 12.5 µL of HiFi HotStart ReadyMix (KAPA Biosystems,
Woburn, MA, USA), 5 µL of each primer (0.2 µM) and microbial DNA (5 ng/µL). PCR amplification
was performed using the following program: Heated lid at 110 ◦C, 95 ◦C for 3 min followed by 25 cycles
at 95 ◦C for 30 s, 55 ◦C for 30 s, and 72 ◦C for 30 s, followed by a final elongation step at 72 ◦C for 5 min.
PCR products were cleaned using the AMPure beads XP purification system (Beckman Coulter, UK)
following Illumina 16S Ribosomal RNA Gene Amplicon instructions. Illumina sequencing adapters
and dual-index barcodes were added to amplicons using the Nextera XT index kit (Illumina, San Diego,
CA, USA). The following program was utilized for the second PCR amplification: 95 ◦C for 3 min
followed by 8 cycles of 95 ◦C for 30 s, 55 ◦C for 30 s and 72 ◦C for 30 s and a final elongation at 72 ◦C for
5 min. A further clean up protocol using AMPure beads XP purification system (Beckman Coulter, UK)
is performed. Amplicons were quantified using the Qubit® 2.0 Fluorometer (Invitrogen) and pooled
equimolar to 4 nM. The pool was denatured with 0.2 M NaOH, further dilution with hybridization
buffer to 20 pM and combined with denatured 30% PhiX. Samples were sequenced on the Illumina
MiSeq platform at the Fundacion FISABIO (Valencia, Spain) facility using a 2 × 300 nucleotide paired
reads protocol. Sequencing raw data were deposited at European Nucleotide Archive (ENA) and
received the following ID: PRJEB14943.
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in Klemenak et al.  [23].  ** Analysis was performed at  the beginning of  the study  (T0) and after 3 
months of treatment (T1). 
2.4. Bioinformatics and Statistical Analyses of NGS Experiment 
Several bioinformatics pipelines have been used to analyse the amount of data produced during 
this project. The first step of analysis was represented by quality controls of the generated raw data, 
which are essential to be confident of the quality of the experimental results. For this purpose, the 
FastQC 0.11.4 software (Babraham Bioinformatics) was used for a rapid visualization of sequences 
quality, then with the prinseq‐lite.pl script sequences have been trimmed according to various quality 
criteria:  first  of  all  sequences with  less  than  50  bp were  eliminated,  then  remaining  reads were 
analyzed with a sliding‐window approach of 20 bp, within this range each sequence with a mean 
quality lower than 20 was removed [26]. 
After that, the fastq‐join tool from the ea‐tools suite [27] was used to join forward and reverse 
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fragilis group (comprising the species B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), 
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Figure 1. Summary of inclusion/exclusion criteria adopted for samples selection. Samples who
showed the right DNA quantification level have been sequenced. * Inclusion criteria are summarized in
Klemenak et al. [23]. ** Analysis was performed at the b ginni g of the study (T0) and after 3 months
of treatment (T1).
2.4. Bioinformatics and Statistical Analyses of NGS Experiment
Several bioinformatics pipelines have been used to analyse the amount of data produced during
this project. The first step of analysis was represented by quality controls of the generated raw
data, which are essential to be confident of the quality of the experimental results. For this purpose,
the FastQC 0.11.4 software (Babraham Bioinformatics) was used for a rapi visualization of sequences
quality, then with the prinseq-lite.pl script sequences have bee trimm d accord to various quality
criteria: first of all sequences with less th n 50 bp were eliminated, then remaining reads wer alyzed
with a sliding-window approach of 20 bp, within this range each sequence with a mean quality lower
than 20 was removed [26].
After that, the fastq-join tool from the ea-tools suite [27] was used to join forward and reverse
sequences. The last quality control step was represented by the elimination of chimeric sequences
using the Usearch tool (http://drive5.com/usearch/). Once high-quality double-stranded reads were
obtained, they were aligned to the 16S reference sequences database at the RDP database project to
identify the microbial community with the RDP classifier tool [28]. RDP classifier outputs have been
then processed through sever l R software pack ges, such as vegan, reshape2, RDPutils and phyloseq
in order to estimate vario s biodiversity indexes and to perform the principle statistics analyses on
taxonomic profiles. Finally, data have been normalized and the function exactTest() of the edgeR
package was used to evaluate the effective microbial differentiation among the studied groups [29].
2.5. Absolute Quantification of Selected Microbial Groups Using Quantitative PCR (qPCR)
Quantification of selected microbial groups i.e., Bidobacterium spp., Lactobacillus spp.,
Bacteroides fragilis group (comprising the species B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron,
B. vulgatus), Clostridium sensu stricto or cluster I and total enterobacteria, was carried out with
real-time PCR on DNA extracted from faecal samples. The assays were performed with a 20 µL
PCR amplification mixture containing 10 µL of Fast SYBR® Green Master Mix (Applied Biosystems,
Nutrients 2016, 8, 660 5 of 16
Foster City, CA, USA), optimized concentrations of primers (Tables 1 and 2), H2O molecular grade
and 2 µL DNA extracted from faecal samples at a concentration of 2.5 ng/µL for all the assays.
The primer concentrations were optimized through primer optimization matrices in a 48-well plate
and evaluating the best Ct/Rn ratio. The different primers were also checked for their specificity using
the database similarity search program nucleotide-nucleotide BLAST [30]. Moreover, to determine
the specificity of amplification, analysis of product melting curve was performed after the last cycle
of each amplification. The data obtained from the amplification were then transformed to obtain the
number of bacterial Log CFU/g faeces according to the rRNA copy number available at the rRNA copy
number database [31]. Standard curves were constructed using 16S rRNA PCR product of type strains
of each target microorganism. PCR products were purified with a commercial kit DNA purification
system (NucleoSpin® Extract II kit, MACHEREY-NAGEL GmbH & Co. KG, Duren, Germany) and the
concentration measured at 260 nm. Serial dilutions were performed and 102, 103, 104, 105, 106, and
107 copies of the gene per reaction and were used for calibration.
Data of microbial counts were subjected to T-test in order to evidence significant differences
between treated and Control group of subjects.
Table 1. Primer sequences and qPCR conditions used in the different assays.
Target Microorganisms Primer Sequences (5′-3′) AmpliconLength (bp) References
Annealing
Temperature
Bifidobacterium spp.
243 [32] 55 ◦CBifTOT-F TCGCGTCYGGTGTGAAAG
BifTOT-R CCACATCCAGCRTCCAC
Lactobacillus spp.
349 [33] 60 ◦CLac-F GCAGCAGTAGGGAATCTTCCA
Lac-R GCATTYCACCGCTACACATG
Bacteroides fragilis group
92 [34] 58 ◦CBfra-F CGGAGGATCCGAGCGTTA
Bfra-R CCGCAAACTTTCACAACTGACTTA
Enterobacteria
195 [35] 63 ◦CEco 1457F CATTGACGTTACCCGCAGAAGAAGC
Eco 1652R CTCTACGAGACTCAAGCTGC
Clostridium cluster I
232 [36] 52 ◦CCI-F1 TACCHRAGGAGGAAGCCAC
CI-F2 GTTCTTCCTAATCTCTACGCAT
Table 2. qPCR amplification protocols and primer concentrations.
Target Microorganisms InitialDenaturation Denaturation Annealing Cycles Fw nM Rev nM
Bifidobacterium spp. BifTOT F/BifTOT-R 95 ◦C, 20 s 95 ◦C–30 s 60 ◦C–30 s 40 200 300
Lactobacillus spp. LAC-F/LAC-R 95 ◦C, 20 s 95 ◦C–30 s 63.5 ◦C–30 s 40 200 200
Bacteroides fragilis group Bfra-F/Bfra-R 95 ◦C, 20 s 95 ◦C–30 s 60 ◦C–30 s 40 300 300
Enterobacteria Eco-F/Eco-R 95 ◦C, 20 s 95 ◦C–30 s 60 ◦C–30 s 40 400 400
Clostridium cluster I CI-F1/CI-F2 95 ◦C, 20 s 95 ◦C–30 s 60 ◦C–30 s 40 200 200
Fw = Primer Forward, Rev = Primer Reverse.
3. Results
3.1. Metagenomic Analysis
The V3-V4 region of 16S rDNA gene was sequenced from 96 DNA samples using the Illumina
MiSeq platform. A total dataset of 4,348,432 filtered high-quality joined reads (excluding the
undetermined sequences) was thus generated, about 46,259 sequences per sample, with a mean
quality between 30 and 35. Two samples were excluded from the whole dataset because they did not
pass the established quality threshold.
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Massive sequencing revealed the presence of six phyla (five belonging to Bacteria and one
to Archaea) with a relative abundance higher than 1%: Firmicutes, Bacteroidetes, Proteobacteria,
Actinobacteria, Verrucomicrobia and Euryarchaeota. The obtained phyla had a different distribution
among the five groups of examined subjects as highlighted in the heat map (Figure 2), in particular in
the Firmicutes and Bacteroidetes phyla.
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Figure 2. Hierarchically clustered heat map: Sample groups are reported in column, while phyla are
reported in row.
In particular, the Firmicutes phylum showed the highest representativeness in the Control group
(accounting for 60%–70% of the total microbial community), whereas it reached 50%–60% in Probiotic
T1 and 40%–50% in the rest of CD patients (Probiotic T0, Placebo T0, and Placebo T1 groups).
On the other hand, the Bacteroidetes phylum was more abundant within CD subjects (20%–40%)
than in the Control group subjects (10%–20%). The other phyla were more evenly distributed among
groups, with the only difference for Proteobacteria and Verrucomicrobia that were more represented in
the Placebo group (~10%–20%). Moreover, the hierarchical cluster analys s combined with the heat
map pointed ou that he Probiotic T1 group occ pied an intermediate position between the Control
group and the rest of CD individuals, being t us considered as an outlier with respect to the other
disease clusters because of its closer relationship with control subjects.
From the comparison between the CD subjects and the Control group microbiota emerged
a marked difference in the ratio of Firmicutes/Bacteroidetes. Figure 3 shows values of ratio
Firmicutes/Bacteroidetes calculated for each group of subjects. CD subjects had a ratio values lower than
the Control group thus meaning a high proportion of Bacteroidetes (Gram negative) with respect to
Firmicutes (Gram positive). The administration of the probiotic for three months was found to increase
the ratio value due to the higher level of Firmicutes phyla than Bacteroidetes.
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Figure 3. The Firmicutes/Bacteroidetes ratio.
Following the data normalization procedure and assignation of statistical significance described
in Material and Method, several comparisons between pair of groups were performed in order to
identify which phyla could distinguish the microbiota of Control group from that of CD patients not
assuming the probiotic formulation, and from Probiotic T1 (Figure 4).
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Statistical analyses confirmed that Firmicutes were significantly lower in CD subjects not receiving
the probiotic formulation compared to Controls and Probiotic group (p < 0.01). Similar results
were found for Actinobacteria that were underrepresented in the CD group and increased after the
administration of bifidobacteria, although not reaching the abundance found in the controls. A further
discernment regarded the Euryarchaeota phylum belonging to Archaea that was almost exclusively
present in the Control group. The same analysis was repeated comparing the microbial composition of
the Control group with the Probiotic groups before and after the probiotic administration (respectively
Probiotic T0 and Probiotic T1) (Figure 5). The comparison highlighted an increase in the relative
abundance of Firmicutes (p < 0.01) and Actinobacteria, due to the effect of probiotic administration.
On the other hand it was possible to observe a slight decrease of the abundance of Proteobacteria while
the Euryarchaeota phylum kept unchanged after the treatment.
The same comparison was carried out at the family taxonomic level. Within the Firmicutes phylum,
two families, which are poorly represented in the Probiotic T0 group, showed instead a higher level
in both the Probiotic T1 and the Control groups: Lactobacillaceae and Gracilibacteraceae. In particular,
both bacterial families showed a significant different abundance between Probiotic T0 and Probiotic T1
groups, whereas no differences were observed between Probiotic T1 and Control groups. In contrast,
Probiotic T1 subjects demonstrated a high percentage of unclassified Deltaproteobacteria families.
Moreover, this analysis enabled identifying the Methanobacteriaceae family as almost exclusively present
within the Control group (Figure 6).
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Figure 5. Significa t differences in phyla relative abundance among Control, Probiotic T0 and Probiotic
T1 groups. The * indicates p < 0.01. Supporting information on relative abundance d p-values is
found in Tables S4 and S5.
The α-diversity indices (Observed, Chao1 and Shannon) were computed for all Operational
Taxonomic Units (OTUs) founded in the five groups of samples as reported in Figure 7. No significant
changes in OTUs composition among the studied groups were observed. Particularly, the observed
raw biodiv sity, as well as the Chao1 index, were slightly hig r in the control samples than in all
the other groups, but the differences were not significant. Even the Shannon index indicated similar
trends among all groups, with a mean value of about 3. This similarity among groups was further
confirmed by the application of Wilcoxon test on these indices, which indicated the totally absence of
significant differences.
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3.2. Quantification of Selected Microbial Groups in Faecal Samples
qPCR analysis was carried out in order to obtain the absolute quantification of selected microbial
groups as a supplementary information able to complete the microbial profile of the examined subjects.
Faecal samples were collected and DNA extracted at two sampling times for CD subjects, on enrolment
(Probiotic T0 + Placebo T0) and at the end of the three months intervention with probiotic or placebo
(T1), and once for healthy individuals (control group). Quantification regarded specific microbial
genera typical of the human gut, Bifidobacterium spp., Clostridium sensu stricto, Bacteroides fragilis
group (comprising the most abundant species in human, i.e., B. fragilis, B. distasonis, B. ovatus,
B. thetaiotaomicron, and B. vulgatus), and larger microbial group, Lactobacillus group, which include
Lactobacillus, Pediococcus, Leuconostoc and Weisella species, and total enterobacteria comprehensives of a
larger number of gram-negative intestinal bacteria. The average microbial counts obtained are shown
in Table 3.
Quantification of Bifidobacterium spp. evidenced a slightly higher value in the subjects affected by
CD at T0 with respect to the control group, although this difference was not significant. The comparison
between subjects belonging to the probiotic group before and after the treatment showed that the
administration of the probiotic formula containing Bifidobacterium breve led to a slight increase of
bifidobacteria counts from 7.64 ± 1.01 to 8.06 ± 0.98 Log CFU/g of faeces. Lactobacillus spp. group
analysis revealed that healthy subjects (Control group) had a higher presence of members of this group
compared to CD patients, which on the contrary, showed a great heterogeneity in the distribution
(Figure 8). ANOVA test revealed that the difference was statistically significant (emphp < 0.01).
The opposite trend was found for members of Bacteroides fragilis group showing a higher median
in CD subjects compared to healthy subjects, as shown in the box plot (Figure 9). The box plot
relative to healthy subjects is shorter than the other one and it also shows a higher median value but a
narrower distribution of the data. ANOVA test revealed that the difference is statistically significant
(p < 0.01). CD patients showed more than 8.70 Log CFU/g of faeces of Bacteroides fragilis group bacteria.
No significant differences were recorded concerning changes in the levels of Bacteroides due to treatment
with probiotics.
With regard to enterobacteria, they were more abundant in the control group compared to CD
patients: 8.29 ± 0.80 and 7.10 ± 1.24 CFU/g, respectively. This trend can also be outlined from
the graphs reported in Figure 10, which clearly shows that the median value of control group is
higher than CD groups, the latter showing a lower level of enterobacteria with a higher heterogeneity.
Furthermore, after the three months of probiotic treatment it was possible to observe a decreased
level of enterobacteria in Probiotic T1 (Figure 10 and Table 3). Regarding Clostridium sensu stricto,
its quantification was lower than the other microbial groups (values from 5.83 to 6.19 Log CFU/g of
faeces). No statistical differences resulted from the comparison between control and CD patients and
between Probiotic and Placebo groups.
Table 3. Mean counts of different microbial groups analysed in stool samples expressed as Log CFU/g
of faeces.
Target
Log No. CFU/g of Faeces
Probiotic Group Placebo Group Control Group
T0 T1 T0 T1 T0
Bifidobacterium spp. 7.64 ± 1.01 8.06 ± 0.98 7.82 ± 0.80 7.74 ± 0.73 7.26 ± 0.92
Lactobacillus spp. 6.87 ± 1.08 6.92 ± 0.95 7.21 ± 0.80 7.04 ± 0.97 7.84 ± 0.58
B. fragilis group 8.73 ± 0.79 8.71 ± 0.77 8.74 ± 0.76 8.84 ± 1.03 7.46 ± 1.47
Enterobacteria 7.10 ± 1.24 6.75 ± 1.29 7.25 ± 1.81 7.63 ± 1.48 8.29 ± 0.80
Clostridium sensu stricto 5.97 ± 0.96 5.83 ± 0.87 6.17 ± 0.95 6.19 ± 0.81 5.86 ± 0.80
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4. Discussion
This work was focused on the characterization of the major changes occurring in the intestinal
microbiota of CD patients on a GFD and on the evaluation of the effects that the administration of
two B. breve strains (B632 and BR03) may have on these patients.
In the last few years a particular attention has been paid on the correlation between gut microbiota
composition and CD. Several studies demonstrated an increase in gram-negative bacteria, mainly
belonging to the Bacteroidetes phylum, at the expense of microorganisms of the Actinobatceria and
Firmicutes phyla in subjects with active disease [7,8,10], in agreement with the results registered in other
chronic inflammatory gastrointestinal diseases such as inflammatory bowel disease [37]. However,
these differences did not allow identifying a coeliac microbiota signature directly linked to CD [6].
Although data regarding the health promoting properties of bifidobacteria and more in general of
probiotic microorganisms are well documented, their role in the treatment of CD has been scarcely
investigated. The two strains administered in this work, B. breve B632 and BR03, are known to
possess anti-inflammatory activity stimulating intestinal cells in vitro to produce IL-6 and IL-10,
respectively [38,39] and have been previously characterized for safety issues such as the absence of
transmissible antibiotic resistance traits and toxicity towards gut epithelial cells. In addition, the
two strains in combination showed a great capability of colonizing the gut of healthy children [40].
In relation to CD, a preliminary important outcome obtained from the administration of the described
probiotic formulation to CD patients was the reduction of pro-inflammatory cytokine TNF-α in blood
samples of CD subjects on a GFD after three months of treatment, as reported in Klemenak et al. [23].
The first interesting evidence that emerges from the present study is the absence of a severe
intestinal dysbiosis in CD patients on a GFD diet, as shown by the comparison of the α-diversity
similarity indices and the absence of statistically significant differences in OTU variability in the
analysed cohort of CD patients with respect to the Control group. On the contrary, literature data
related to active disease patients non-adherent to a GFD showed the presence of extensive changes
in the microbial composition [8]. Therefore, the strict adherence to the GFD partially recovers the
intestinal equilibrium status.
However, the results obtained in this study showed a significant quantitative difference in
some microbial groups by qPCR and by metagenomic analysis in CD patients with respect to the
Control group. The elaboration of the microbial relative abundance data obtained by Illumina MiSeq
sequencing were able to clearly separate CD subjects from the Control group ones. The lower number
of Bacteroidetes phylum in CD patients with respect to the Control group was supported by B. fragilis
group quantification by qPCR and it is consistent with the results of another study on CD patients
on GFD [7]. The obtained results are also in agreement with the observation that CD subjects present
an imbalance in the Firmicutes/Bacteroidetes ratio, usually lower in CD patients, and this ratio is not
completely restored in patients under a GFD [41]. Moreover, the probiotic administration induced
an evident increase of Firmicutes abundance while maintaining a similar percentage of Bacteroidetes,
thus resulting in a higher value of the Firmicutes/Bacteroidetes ratio. In addition, the Control group
microbiota seems to be characterized by a higher percentage of Actinobacteria and Euryarchaeota.
The association between CD disease status and a lower presence of Actinobacteria has already been
described [42]. Particularly interesting, although not yet described in the literature, is the result
regarding the Euryarchaeota phylum, which is highly represented in the Control group, but almost
absent in the coeliac subjects. The same applies for the Methanobacteriaceae family. This evidence could
conceivably be linked to differences in the dietary habits of the two groups of subjects. Recent research
works focused on Euryarchaeota highlighted their ability to promote polysaccharide degradation and
absorption of fatty acids, thus they seem to play a role in energy extraction from degradation of organic
compounds [43]. Grain is the most common source of polysaccharides in modern human populations,
thus the important reduction of archaea microorganisms within coeliac group on GFD is linked to
their different nutritional status, in particular to the compliance of the GFD and the consequent lower
polysaccharide intake.
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Focusing on the effects of the administration of the B. breve strains on microbial composition,
an increase of members of the Actinobacteria phylum (NGS) and bifidobacteria (qPCR) have been
detected in the CD subjects after three months of probiotic supplementation, although the increase
was not statistically significant. One of the possible reasons could be the short duration of the
treatment, furthermore it is already known that, after the weaning period, the microbiota is resilient to
changes [44]. The treatment with the B. breve strains has therefore not caused major changes at the level
of the genus or phylum to which the probiotic belongs, as it might have been expected, but the intake
of the probiotic has nevertheless acted as a “trigger” element for the increase of Firmicutes and the
restoration of the physiological Firmicutes/Bacteroidetes ratio. By reaching the microbial family level of
analysis, it was possible to get more details on the effect of probiotic administration, allowing to reach
the conclusion that two Firmicutes families (Lactobacillaceae and Gracilibacteraceae) changed their relative
abundances upon probiotic treatment (Probiotic T1 group), particularly Lactobacillaceae that reached
almost the values that characterized the Control group. Other studies have also observed a lower
presence of Lactobacillaceae in CD patients, indicating a close relationship between this pathological
condition and the bacterial family [9]. This means that the probiotic has restored the normal amount
of Lactobacillaceae members belonging to these families within the treated individuals. It remains to
be explained why the administration of such a Bifidobacterium strain have affected Lactobacillaceae
species. This could be related to a high ability of Bifidobacterium to deep influence gut microflora
composition, by enhancing the blooming of some species and antagonizing others probably by the
effect of the production of metabolites such as acetic acid [45]. In particular, there are evidences that
Bifidobacterium support Lactobacillaceae development [46]. Moreover, it is highly probable that the
decrease of TNF-α observed within treated individuals is closely linked to the increase of lactobacilli,
with their anti-inflammatory function promoted by the administration of Bifidobacterium [47,48].
5. Conclusions
In conclusion, the present study demonstrated that three months administration of B. breve
strains could make the intestinal microbiota of coeliac patients more similar to that of healthy
individuals, restoring the abundance of some microbial communities that characterize the typical
physiological condition.
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